Archive: Company News
BellaSeno Appoints Dr. Thomas Lingner as Chief Technology Officer and Inga Freyert as VP Quality and Regulatory Affairs
— Further expansion of management expertise to accelerate BellaSeno´s market entry
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that Dr. Thomas Lingner was appointed Chief Technology Officer and Inga Freyert was promoted to VP Quality and Regulatory Affairs.
MetrioPharm Establishes Scientific Advisory Board of Seasoned Immunology and Pediatric Experts
— The new advisors will supply expertise in immunology, pathology, inflammatory processes and in MetrioPharm’s lead indication Duchenne muscular dystrophy
— Advisors have previously collaborated with MetrioPharm on strategic and scientific projects
— Advisors bring expertise to further advance MetrioPharm´s pipeline
MetrioPharm AG, a clinical stage biotech company developing drugs for inflammatory and infectious diseases, today announced that it has established a Scientific Advisory Board (SAB). Read more…
BellaSeno’s 3D-printed Resorbable Scaffold Successfully Used in Critical-Size Large Segmental Radius Bone Defect at Hannover Medical School
— Trauma patient suffered from third degree open infected fracture of its radial shaft after injury by a bullet
— Graft vascularization was achieved by embedding vascular pedicle into the scaffold
— Recently published as a case report in the Journal of Personalized Medicine
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, announced today that a team at the Hannover Medical School, Clinic for Trauma Surgery, led by Prof. Dr. med. Philipp Mommsen, successfully used a customized, resorbable bone replacement scaffold produced by BellaSeno to reconstruct a 14 cm segmental bone defect of the radial shaft after third degree open infected fracture due to traumatic gunshot injury.
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
– Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria
Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the Company has received fast-track designation for its novel anti-infective OMN6 from the U.S. Food and Drug Administration (FDA). Fast track expedited review is designated to investigational drugs that treat a serious or life-threatening condition and fill an unmet medical need.